Business, energy, technology, markets and global industry news from Business News Today

cell therapy

PharmaDeviceNews cell therapy
Representative image: Retinal imaging analysis highlights the clinical delivery and manufacturing challenges facing Lineage Cell Therapeutics as OpRegen advances in geographic atrophy and OPC1 progresses in spinal cord injury.
Pharma & Biotech

Can Lineage turn early retinal repair signals into a credible late-stage OpRegen pathway?

Discover why Lineage Cell Therapeutics’ OpRegen and OPC1 programmes now face critical delivery, trial design and manufacturing tests.

Read More
Orca Bio wins FDA approval for TREGZI in matched-donor blood cancer transplants
Pharma & Biotech

Orca Bio’s TREGZI enters the transplant market with a strong Phase 3 advantage

See how Orca Bio’s TREGZI FDA approval could reshape blood cancer transplants, reduce chronic GVHD and test cell therapy scale-up.

Read More
Pharma & Biotech

Qihan Biotech gains FDA momentum for QT-019B as allogeneic CAR-T ambitions grow

Find out how Qihan Biotech’s QT-019B FDA designations could reshape autoimmune CAR-T development and what risks remain.

Read More
Representative image of advanced CAR T-cell therapy research and infusion monitoring, reflecting CARsgen Therapeutics’ CT0596 and CT1190B data in multiple myeloma and B-cell lymphoma.
Pharma & Biotech

How CARsgen’s EHA 2026 data could change investor debate around allogeneic CAR T

Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.

Read More
Representative image of researchers working in a modern cell therapy laboratory, reflecting T-CURX’s acquisition of Pantherna Therapeutics and the growing race to advance in vivo CAR-T, mRNA delivery and lipid nanoparticle technologies.
Pharma & Biotech

Why T-CURX’s Pantherna acquisition could matter for the future of cell therapy manufacturing

T-CURX and Pantherna are combining CAR-T, mRNA and LNP platforms. Europe’s in vivo cell therapy race just became more serious.

Read More
Representative image of a clinical oncology research setting as PeproMene Bio’s PMB-CT01 BAFF-R CAR T data highlight a potential new treatment path for relapsed B-cell lymphoma after CD19 CAR T failure.
Pharma & Biotech

PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma

PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.

Read More
Pharma & Biotech

How NewcelX Ltd. is pursuing durable islet graft survival in the race for a functional diabetes cure

How NewcelX Ltd. is advancing NCEL-101 toward a functional diabetes cure through durable islet graft survival and immune protection strategies.

Read More
Representative image: Scientists work inside an advanced iPSC biomanufacturing lab as FUJIFILM Cellular Dynamics’ Madison facility highlights growing demand for stem cell manufacturing, regenerative medicine infrastructure and cell therapy scale-up.
Pharma & Biotech

Can FUJIFILM’s Madison facility help solve the scale problem in stem cell manufacturing?

iPSC demand is rising fast. FUJIFILM’s Madison facility tests whether stem cell manufacturing can keep pace with pharma and cell therapy needs.

Read More
Pharma & Biotech

Charles River and MEDIPOST deepen cell therapy testing push across APAC and North America

Cell therapy scale-up is not just a science problem. Charles River and MEDIPOST are targeting the GMP testing bottleneck.

Read More
Pharma & Biotech

Can Cellular Intelligence revive Novo Nordisk’s shelved Parkinson’s cell therapy programme?

Novo shelved the asset, but Cellular Intelligence sees a platform test. Parkinson’s cell therapy now faces its harder commercial trial.

Read More